Assertio

Assertio is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia (diclofenac potassium for oral solution) for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor (diclofenac potassium) liquid-filled capsules for relief of mild to moderate acute pain, and Lazanda (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients. See Important Safety Information for Gralise, Cambia, Zipsor, and Lazanda.

Assertio, established in 1995 and headquartered in United States, North America., specializes in investments across Health Care, Wellness. Their recent investments include LGS Foundation. The highest investment round they participated in was $800.0K. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.